Palmer, D., Webber, B., Patel, Y., Johnson, M., Kariya, C., Lahr, W., Parkhurst, M., Gartner, J., Prickett, T., Lowery, F., Kishton, R., Gurusamy, D., Franco, Z., Vodnala, S., Diers, M., Wolf, N., Slipek, N., McKenna, D., Sumstad, D., Viney, L., Henley, T., Bürckstümmer, T., Baker, O., Hu, Y., Yan, C., Meerzaman, D., Padhan, K., Lo, W., Malekzadeh, P., Jia, L., Deniger, D., Patel, S., Robbins, P., Scott McIvor, R., Choudhry, M., Rosenberg, S., Moriarity, B., & Restifo, N. (n.d.). 333 Targeting the apical intracellular checkpoint CISH unleashes T cell neoantigen reactivity and effector program. Journal for immunotherapy of cancer, 8, A359. http://access.bl.uk/ark:/81055/vdc_100144724360.0x000005